What changed for Alzheimer's Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Alzheimer's Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 482 to 483 (+1)
- Trials on record 3,129 to 3,158 (+29)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Alzheimer's Disease in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 103 trials tracked for Alzheimer's Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05318976 · results posted 29 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at an experimental treatment called XPro1595 in people with early or mild Alzheimer's disease. A total of 207 participants were enrolled — 140 received XPro1595 injections (at a dose of 1.0 mg/kg) and 67 received a placebo (an inactive dummy injection). Of those, 120 in the XPro1595 group and 62 in the placebo group completed the 24-week study. The trial was primarily measuring changes in a combined score of six thinking and memory tests, known as the EMACC, over that period. Several secondary measures were also tracked...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03876314 · results posted 12 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 180 older adults across two groups: 98 in a Physical Activity Condition (PAC) and 82 in a Usual Care Control (UCC). The trial was measuring whether a physical activity programme was associated with changes in certain thinking and memory skills over about 12 months. Participants were tested at the start of the trial (pre-test), at around 6 months (mid-test), and at around 12 months (post-test). By the end of the trial, 76 people in the PAC group and 67 in the UCC group completed all measurements. The reported data sho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05744401 · results posted 25 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05744401) enrolled 197 people in total across four groups receiving different doses or dosing schedules of a drug called AL002. The groups were: 41 people receiving 15 mg/kg, 49 receiving 40 mg/kg, 43 receiving 60 mg/kg, and 64 in a "titration cohort" (meaning they started on a lower dose and had it gradually increased). The trial was primarily measuring how many participants experienced various types of adverse events (unexpected medical occurrences, which can include anything from side effects to illnesses), as well as c...
-
NCT06831812 · results posted 24 February 2026
According to the results reported on ClinicalTrials.gov, this trial tested a vaccine called AV-1959R, which is being investigated as a potential approach to Alzheimer's disease. It targeted a protein called amyloid-beta (Aβ), which builds up in the brains of people with Alzheimer's. A total of 16 people took part, divided into four groups: six received a lower dose (100 micrograms) of AV-1959R, six received a higher dose (300 micrograms), and four received a placebo (a harmless comparison injection with no active ingredient). All 16 participants completed the trial. The reported data shows th...
-
NCT04857060 · results posted 12 January 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a programme called Advance Care Planning (ACP) — a process where people discuss and document their wishes about future medical care. The trial used a "stepped wedge" design, meaning different groups of participants switched from receiving usual care to receiving the ACP programme (which involved a trained educator and a video-assisted discussion) at different time points across the study. In total, across all steps, thousands of patients and a smaller number of caregivers (family members or support people) took part...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04592874 · results posted 29 October 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called AL002 in people with Alzheimer's disease. A total of 356 people took part, split across four groups: three groups received different doses of AL002 (15 mg/kg, 40 mg/kg, or 60 mg/kg), and one group received a placebo (an inactive treatment). The main thing the trial was measuring was how scores on a standard Alzheimer's assessment tool — called the CDR-SB — changed over roughly two years. The CDR-SB runs from 0 (normal) to 18 (severe dementia), with higher scores meaning greater impairment....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05771428 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05771428) tested an investigational drug called ABBV-552 at three different doses (1 mg, 5 mg, and 15 mg) compared to a placebo (an inactive treatment) in people with Alzheimer's disease. A total of 263 people started the trial across the four groups, and most completed it — 63 in the placebo group, 61 in the 1 mg group, 61 in the 5 mg group, and 60 in the 15 mg group. The main thing being measured was how participants' thinking and memory abilities changed over 12 weeks, using a standardised test called the ADAS-Cog 14, w...
-
NCT03446001 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03446001) looked at a drug called TRx0237 in people with Alzheimer's disease. A total of 598 participants were enrolled across three groups: 266 received a control (comparison) treatment, 80 received TRx0237 at 8 mg per day, and 252 received TRx0237 at 16 mg per day. The trial ran in two phases — a blinded phase (where participants did not know which treatment they were on) and an open-label phase (where all participants received TRx0237 at 16 mg per day). The main things being measured were changes in thinking and memory...
-
NCT03507790 · results posted 11 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03507790) tested an investigational drug called CT1812 in people with Alzheimer's disease. A total of 153 people took part — 51 in each of three groups: one group received a lower dose of CT1812 (100 mg), one received a higher dose (300 mg), and one received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring how many participants experienced unwanted health events (called adverse events) after starting treatment, and secondarily looking at changes in certain biological markers measur...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04556097 · results posted 5 August 2025
According to the results reported on ClinicalTrials.gov, this trial involved four groups of participants. Two groups were made up of people with dementia (PWD) — 206 in the intervention group and 187 in the control group. The other two groups were nurse care managers (NCM) — 15 in each group. The trial was measuring whether a care programme made a difference to how often people with dementia visited the emergency department, and how much distress their carers experienced, over a six-month period. The reported data shows that in the six months after the programme, people in the intervention gr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03706261 · results posted 1 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 145 participants in total, with 126 completing the study and 19 not completing it. The trial was investigating brain imaging measurements — specifically, it used two different radioactive tracers (substances that can be tracked by a scanner) to look at deposits in the brain associated with memory and brain health. One tracer, called 18F-MK-6240, was used to measure a protein called tau, and the other, called 18F-Florbetaben, was used to detect a substance called amyloid. The study aimed to explore whether these brain...
-
NCT05063539 · results posted 28 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called LY3372689 in people with early symptomatic Alzheimer's disease. Participants were randomly assigned to receive one of two doses of the drug (0.75 mg or 3 mg) or a placebo (an inactive treatment used for comparison). A total of 327 people started the treatment phase — 110 in the 0.75 mg group, 109 in the 3 mg group, and 108 in the placebo group. The trial used several rating scales to measure changes in thinking and daily functioning over time, and included both an overall group of particip...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04408755 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04408755) looked at a medication called AVP-786 (tested at two different doses — a lower dose called AVP-786-18 and a higher dose called AVP-786-42.63) compared to a placebo (a dummy pill with no active ingredient) in people with agitation related to Alzheimer's disease. A total of 184 people enrolled and went through an initial placebo lead-in phase; 173 completed that phase and 173 were then randomly assigned to one of three groups — 56 to placebo, 60 to the lower dose, and 57 to the higher dose — for the main comparison...
-
NCT04994483 · results posted 25 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04994483) enrolled 804 people with Alzheimer's disease — 403 in the simufilam 100 mg group and 401 in the placebo (dummy pill) group. The trial ran for 52 weeks and was measuring changes in cognition (thinking and memory), daily functioning, and behaviour-related symptoms using several standardised rating scales. By the end of the study, 310 people in the simufilam group and 325 in the placebo group had completed the full 52 weeks. The reported data shows the following changes in scores from the start of the trial to Week...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05575076 · results posted 14 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,081 people who had previously completed one of two earlier simufilam studies. All participants received simufilam at a dose of 100 mg. The trial was an open-label extension study, meaning everyone received the same treatment with no placebo comparison group. Of the 1,081 people who started, 300 completed the study and 781 did not complete it. The main thing the trial was set up to measure was how many participants experienced adverse events (that is, any unwanted or unexpected medical occurrences) over the longer te...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05516134 · results posted 29 April 2025
According to the results reported on ClinicalTrials.gov, this trial involved 51 people across three groups: 26 people receiving the treatment (25 of whom completed the study), 9 family members, and 16 staff members. The trial was measuring how engaged people with dementia appeared during activities, using a tool called the Menorah Park Engagement Scale (MPES). This scale observes and scores different types of engagement — such as actively participating, passively watching, being distracted by something unrelated, or not engaging at all (for example, sleeping or staring into space). It also rec...
-
NCT05310071 · results posted 23 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05310071) enrolled 1,024 participants in total — 344 in the placebo group and 680 in the aducanumab group. The trial was studying aducanumab, a medicine being investigated for Alzheimer's disease. It measured changes over roughly 78 to 106 weeks (about one and a half to two years) across several scales that assess memory, thinking ability, and day-to-day functioning. Notably, the reported data shows that zero participants in either group were recorded as having "completed" the study, and all participants were listed as "no...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04948450 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 30 in an intervention group and 30 in a control group. The trial was measuring two main things: how well participants stuck to their scheduled sessions (called "adherence") and how many stayed in the study all the way through (called "retention"). It also looked at several aspects of thinking and memory, including overall mental function, planning and organisational skills (executive function), and attention. The reported data shows that, for adherence, the intervention group attended approximate...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04241068 · results posted 21 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04241068) looked at a single group of participants receiving a medicine called aducanumab. A total of 1,696 people started the main treatment period, of whom 1,118 finished it. A further follow-up phase then began with 1,041 participants, and 508 of those completed it. The trial was primarily measuring safety-related events — in other words, it was tracking unwanted medical occurrences and other health events that happened while people were taking the medicine. The reported data shows that during the main treatment period...
-
NCT06424236 · results posted 4 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06424236) enrolled 73 participants across three groups. All participants had previously taken part in a double-blind study where they received one of three treatments — a placebo, a drug called solanezumab, or a drug called gantenerumab — and then moved into an open-label extension (OLE) phase where everyone received gantenerumab. The trial was measuring changes in brain scans and thinking/memory tests over up to 156 weeks (about three years). Of the 73 who started, only 13 completed the study — 4 from the placebo group, 2...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03461276 · results posted 3 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03461276) involved 124 participants in total — split evenly into two groups of 62 — and ran in two parts. Part A lasted 18 to 24 months, and Part B lasted a further 18 months. The trial was testing an experimental vaccine called ABvac40, which is designed to prompt the body to produce antibodies (proteins made by the immune system) against a substance called Aβ40, which is associated with Alzheimer's disease. The main thing the trial set out to measure was the change in the level of those antibodies in participants' blood...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04730635 · results posted 28 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04730635) enrolled 44 people in total — 29 in the donepezil (medication) group and 15 in the placebo (dummy treatment) group. Most participants finished the study: 28 in the donepezil group and 14 in the placebo group completed it, with one person dropping out from each group. The trial was looking at whether donepezil had any effect on a specific type of visual memory test called the One Card Learning task, which asks participants to recognise patterns and is used to assess memory, in people with mild cognitive impairment...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05602727 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05602727) tested an investigational drug called MK-1942 in people with Alzheimer's disease. A total of 99 participants were enrolled — 35 received the lower dose (5 mg), 31 received the higher dose (15 mg), and 33 received a placebo (a dummy treatment with no active ingredient). The trial ran for 12 weeks and measured changes in thinking and memory abilities, day-to-day functioning, and overall clinical impression, as well as tracking unwanted medical events that occurred during the study. The reported data shows the foll...
-
NCT04325204 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a faith-based programme called "Faith-HAT" for pairs of people — one person living with dementia and their carer (called "dyads"). The trial enrolled 27 carers and 27 people living with dementia (54 people in total). The study was measuring whether the programme was practical to run — specifically, how quickly researchers could recruit participants, how often participants used the programme, and how many people stayed in the study through to the end. It also measured carers' feelings of burden, stress, and symptoms o...
-
NCT05256134 · results posted 9 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05256134) enrolled 25 people in total — 12 in the placebo group and 13 in the gantenerumab group. Gantenerumab is a medicine that was being investigated for Alzheimer's disease. The trial was measuring changes in thinking and memory abilities over time, as well as how long it took for participants' condition to progress. Notably, the reported data shows that none of the participants completed the study — all 25 are listed as having not completed it — which is important context for interpreting the numbers below. The repor...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04437511 · results posted 20 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04437511) enrolled 860 people in the donanemab group and 876 in the placebo group, with 853 and 874 respectively going on to receive at least one dose. The trial was studying donanemab, an investigational treatment for Alzheimer's disease, and was measuring changes in participants' thinking abilities and capacity to carry out daily activities over time. Participants were assessed using several standardised rating scales, with the main focus on a combined score called the iADRS (which blends tests of memory and thinking wit...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04374253 · results posted 8 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04374253) enrolled a total of 1,382 participants across four groups. Participants had previously taken part in related studies (called the GRADUATE trials) and were divided based on whether they had received gantenerumab (a drug being investigated for Alzheimer's disease) or a placebo, and whether they went on to join a follow-on study period called the "Graduate OLE" (Open-Label Extension). The trial was primarily measuring safety-related events — things like unwanted medical occurrences, brain imaging changes, and reacti...
-
NCT03095417 · results posted 27 March 2024
According to the results reported on ClinicalTrials.gov, this trial looked at whether different combinations of physical exercise, cognitive (brain) training, and stretching-based activities had any measurable impact on thinking and physical abilities in older adults. A total of 153 people started the trial and were split into four groups: one group did both physical exercise and cognitive training; a second did physical exercise with a cognitive control activity; a third did cognitive training with stretching; and a fourth did cognitive control and stretching activities only. By the end of th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03444870 · results posted 30 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03444870) looked at a drug called gantenerumab compared to a placebo (an inactive treatment) in people with Alzheimer's disease. The main part of the trial — called the double-blind treatment (DBT) period — involved 486 people in the placebo group and 499 people in the gantenerumab group from the global study, plus a smaller separate group of 68 participants from China. The trial ran for approximately 116 weeks (just over two years). The main thing being measured was how participants' thinking and everyday functioning chan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04339413 · results posted 18 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04339413) involved two groups of participants — 59 people in the "SCarlet RoAD" group and 57 people in the "Marguerite RoAD" group — who received the investigational medicine gantenerumab. The trial was primarily measuring a range of safety-related outcomes, including unwanted medical events (called adverse events), serious medical events, reactions at the injection site, certain types of brain imaging abnormalities, signs of suicidal thoughts or behaviour, and whether participants' immune systems produced antibodies again...
See all 103 reported results for Alzheimer's Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, Alzheimer's Disease currently attracts a very large amount of public research investment from the United States government, and that level of support has remained broadly steady from one year to the next. This pattern of sustained, substantial funding suggests that Alzheimer's Disease is regarded as a serious research priority by one of the world's largest medical re...
See the full Alzheimer's Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.